ABSTRACT
BACKGROUND: Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS-CoV-2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS-CoV-2 infections modify the risk of high Lp(a) concentrations for IHD or thromboembolic events during the first 8.5 months follow-up of the pandemic. METHOD: Cohort study using data from the UK Biobank during the SARS-CoV-2 pandemic. Baseline Lp(a) was compared between SARS-CoV-2 positive patients and the population controls. RESULTS: SARS-CoV-2 positive patients had Lp(a) concentrations similar to the population controls. The risk for IHD increased with higher Lp(a) concentrations in both, the population controls (n = 435,104) and SARS-CoV-2 positive patients (n = 6937). The causality of the findings was supported by a genetic risk score for Lp(a). A SARS-CoV-2 infection modified the association with a steeper increase in risk for infected patients (interaction p-value = 0.03). Although SARS-CoV-2 positive patients had a five-times higher frequency of thromboembolic events compared to the population controls (1.53% vs. 0.31%), the risk was not influenced by Lp(a). CONCLUSIONS: SARS-CoV-2 infections enforce the association between high Lp(a) and IHD but the risk for thromboembolic events is not influenced by Lp(a).
Subject(s)
COVID-19/diagnosis , Lipoprotein(a)/blood , Myocardial Ischemia/epidemiology , Nasopharynx/virology , SARS-CoV-2/isolation & purification , Thromboembolism/epidemiology , Adult , Aged , COVID-19/blood , COVID-19 Nucleic Acid Testing , Case-Control Studies , Cohort Studies , Female , Humans , Intensive Care Units , Male , Middle Aged , Risk Factors , SARS-CoV-2/genetics , Thromboembolism/etiologyABSTRACT
The above article was published online with inverted given and family names. The correct presentation has been corrected above.
Subject(s)
Betacoronavirus/drug effects , Coronavirus Infections/drug therapy , Guillain-Barre Syndrome/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Pneumonia, Viral/drug therapy , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Guillain-Barre Syndrome/complications , Guillain-Barre Syndrome/virology , Humans , Immunization, Passive , Italy , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , SARS-CoV-2 , COVID-19 SerotherapyABSTRACT
Recently, some cases of Guillain Barré syndrome (GBS) and Miller Fisher (MF) have been reported, following COVID-19 infection1-2-3 . We report two different clinical manifestation of Covid-19 related GBS , one is a GBS/MF overlap syndrome, the other one an Acute Motor Sensory Axonal Neuropathy (AMSAN) with massive vegetative impairment, both highly responsive to intravenous immunoglobulins.